Mauritania vs Pre-demographic dividend: Access to anti-retroviral drugs, male
Mauritania
97.0%
in 2024
Pre-demographic dividend
80.4%
in 2024
Mauritania rank
2nd
Pre-demographic dividend rank
5th
Access to anti-retroviral drugs, male over time
- Mauritania
- Pre-demographic dividend
How they compare
Mauritania currently reports 97.0% against 80.4% in Pre-demographic dividend, a difference of 16.6%.
That makes Mauritania's figure about 1.2 times Pre-demographic dividend's.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Pre-demographic dividend ahead.
Mauritania ranks 2nd and Pre-demographic dividend ranks 5th of 141 countries.
Across the 3 decades both report, Mauritania averaged higher in 1 and Pre-demographic dividend in 2.
Head to head by decade
| Decade | Mauritania | Pre-demographic dividend | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.7% | 5.7% | 2.0% | Pre-demographic dividend |
| 2010s | 33.4% | 37.6% | 4.2% | Pre-demographic dividend |
| 2020s | 79.4% | 71.5% | 7.9% | Mauritania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Mauritania or Pre-demographic dividend?
- Mauritania, at 97.0% against 80.4% in Pre-demographic dividend as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Mauritania and Pre-demographic dividend?
- 16.6%, with Mauritania ahead.
- How many years of comparable data are there for Mauritania and Pre-demographic dividend?
- 25 years are reported by both, from 2000 to 2024.
- How do Mauritania and Pre-demographic dividend rank globally for access to anti-retroviral drugs, male?
- Mauritania ranks 2nd and Pre-demographic dividend ranks 5th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.